"Official medicines" is the best online drugstore.

World’s leading meds delivered to your door – and you don’t even need a prescription! Only certified, first class drugs on offer! Buy more and spend less with our great discount system.

The meds you need, reliable and hassle free! Top products of top brands.

The only pharmacy shop you will ever need! Approved drugs available without prescription. Best deals, unmatched service and shipping. 100% safe!


(KWIN-ih-deen)
Quinidine Sulfate
Quinidex Extentabs, Quinora,  Apo-Quinidine
Quinidine Gluconate
Quinaglute Dura-Tabs, Quinalan,  Quinate
Quinidine Polygalacturonate
Cardioquin
Class: Antipsychotic

 Action Depresses myocardial excitability, conduction velocity and contractility; prolongs effective refractory period and increases conduction time; indirect anticholinergic effects; may decrease vagal tone at low doses paradoxically increasing conduction through the AV node.

 Indications Treatment of premature atrial, atrioventricular junctional, and ventricular contractions; treatment of paroxysmal supraventricular tachycardia, paroxysmal atrioventricular junctional rhythm, atrial flutter, paroxysmal and chronic atrial fibrillation, and paroxysmal ventricular tachycardia not associated with complete heart block; maintenance therapy after electrical conversion of atrial fibrillation or flutter.

Quinidine gluconate (IV administration): Treatment of life-threatening Plasmodium falciparum malaria.

 Contraindications Myasthenia gravis; history of thrombocytopenic purpura associated with quinidine administration; digitalis intoxication; complete heart block; left bundle branch block; complete atrioventricular (AV) block with AV nodal or idioventricular pacemaker; aberrant ectopic impulses and abnormal rhythms because of escape mechanisms; history of drug-induced torsade de pointes; history of long QT syndrome.

 Route/Dosage

The following oral doses are expressed as quinidine sulfate salt:

Premature Atrial and Ventricular Contractions

ADULTS: PO 200 to 300 mg tid/qid. CHILDREN: PO 30 mg/kg/day or 900 mg/m 2/day in 5 divided doses.

Paroxysmal Supraventricular Tachycardia

ADULTS: PO 400 to 600 mg q 2 to 3 hr until event is abated.

Atrial Flutter

Administer after digitalization and individualize dose.

Conversion of Atrial Fibrillation

ADULTS: PO 200 mg q 2 to 3 hr for 5 to 8 doses, then maintain with 200 to 300 mg tid to qid (immediate-release tablets) or 300 to 600 mg bid to tid (sustained-release tablets); do not exceed 3 to 4 g/day.

QUINIDINE GLUCONATE

ADULTS: PO 324 to 648 mg (1 to 2 tablets) q 8 to 12 hr.

Quinidine Polygalacturonate

ADULTS: PO Maintenance dose: 275 mg q 8 to 12 hr.

PARENTERAL QUINIDINE GLUCONATE

ACUTE TACHYCARDIA: ADULTS: IM 600 mg initially, then 400 mg prn up to q 2 hr. CHILDREN: IV 2 to 10 mg/kg/dose q 3 to 6 hr prn. P. FALCIPARUM MALARIA: ADULTS: IV 15 mg/kg infused over 4 hr initially, then 7.5 mg/kg over 4 hr q 8 hr for 7 days or until oral therapy can be instituted or 10 mg/kg over 1 to 2 hr initially, then 0.02 mg/kg/min for up to 72 hr or until oral therapy can be instituted.

 Interactions

Amiodarone, antacids, cimetidine, verapamil: May increase quinidine levels. Anticoagulants: May increase effect of anticoagulant; may cause hemorrhage. Barbiturates, nifedipine, primidone, sucralfate: May decrease quinidine levels. Beta-blockers: May increase effect of beta-blocker. Dextromethorphan: May increase plasma dextromethorphan concentrations. Digitoxin, digoxin: May increase digoxin plasma levels. Hydantoins: May reduce therapeutic effect of quinidine. Nondepolarizing neuromuscular blocking agents, succinylcholine: May increase neuromuscular blockade effect. Propafenone: Increased propafenone levels. Rifampin: May increase quinidine metabolism.

 Lab Test Interferences Triamterene will interfere with the fluorescent measurement of quinidine levels.

 Adverse Reactions

CV: Widening of QRS complex; cardiac asystole; ventricular ectopy; hypotension; paradoxical tachycardia. CNS: Headache; fever; vertigo; excitement; confusion; delirium; syncope. DERM: Rash; urticaria; pruritus; flushing; photosensitivity. EENT: Mydriasis; blurred vision; photophobia, diplopia, night blindness; tinnitus. GI: Nausea; vomiting; anorexia; abdominal pain; diarrhea. GU: Lupus nephritis. HEPA: Hepatitis. HEMA: Acute hemolytic anemia; agranulocytosis; thrombocytopenic purpura. OTHER: Lupus erythematosus-like syndrome; cinchonism (headache, tinnitus, nausea, disturbed vision, deafness, dizziness, vertigo, lightheadedness); hypersensitivity reactions; arthralgia; myalgia.

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Atrial flutter or fibrillation: Pretreat these patients with digitalis preparation. Bioequivalency: Different salts have different amounts of quinidine base. Do not interchange without taking this into consideration. Cardiotoxicity: May occur; immediately discontinue drug. Hepatotoxicity (including granulomatous hepatitis): Has occurred. Consider possibility if unexplained fever or elevated hepatic enzymes develop. Hypersensitivity reactions: May occur; administer single 200 mg tablet of quinidine sulfate or 200 mg IM injection of quinidine gluconate before starting therapy to determine if patient has idiosyncrasy to quinidine. Malaria: Dose schedules may result in hypotension, ECG changes, and cinchonism. Parenteral therapy: Use only when oral therapy is not possible or when rapid therapeutic effect is required. Potassium balance: Effect of quinidine is enhanced by potassium and reduced if hypokalemia is present. Renal, hepatic, or cardiac impairment: Use drug with caution because of potential for toxicity. Syncope: Occasionally occurs in patients on long-term therapy; may be fatal. Often caused by torsades de pointes. Vagolytic effects: May antagonize vagal maneuvers or administration of cholinergic drugs used to terminate paroxysmal supraventricular tachycardia.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

  • Use IV route only when rapid response is needed or oral route is not feasible.
  • Give test dose of 200 mg as ordered to evaluate intolerance/sensitivity.
  • Position patient supine during IV administration to minimize hypotension.
  • For direct IV push, administer slowly at 1 ml/min.
  • For intermittent IV infusion, dilute 800 mg/50 ml or more with D5W; give at a rate of 16 mg/min or less. Use infusion device for accuracy/safety.
  • Administer IM injection in deltoid muscle.
  • Give oral preparation with full glass of water on empty stomach (1 hr before or 2 hr after other medication) to enhance absorption; if GI distress develops, administer with or just after meal.
  • Do not break or crush or allow patient to chew sustained-release preparations. Instruct patient to swallow whole.
  • Store vial at room temperature. Parenteral solution must be clear and colorless. Solution is stable for 24 hr.
  • Store tablets in tight, light-resistant container.

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Determine if patient has myasthenia gravis.
  • When drug is used as antiarrhythmic agent, assess ECG prior to and continuously throughout therapy. Therapy is discontinued if severe heart block occurs (50% widening of QRS complex, PR, or QT interval are prolonged) or tachycardia or frequent ventricular ectopic beats develops.
  • Obtain baseline BP and pulse and assess continuously during therapy.
  • Monitor CBC and hepatic and renal function tests during long-term therapy.
  • When drug is used as antimalarial agent, monitor BP, ECG, and plasma quinidine levels closely during therapy, especially if drug is being administered parenterally.
  • If patient had been receiving digoxin, measure digoxin concentration to ensure it does not increase to toxic levels.
  • Observe for hypotension, tachycardia, and arrhythmias.
OVERDOSAGE: SIGNS & SYMPTOMS
  Cardiorespiratory depression, lethargy, confusion, coma, seizures, headache, paresthesia, vertigo, vomiting, abdominal pain, diarrhea, nausea, tachyarrhythmias, depressed automaticity and conduction, hypotension, syncope, heart failure, cinchonism, hypokalemia, visual/auditory disturbances, tinnitus, acidosis

 Patient/Family Education

  • Instruct patient/family to administer medication around clock as directed and to continue taking medication even if symptoms improve.
  • Advise patient to take with food if GI upset occurs.
  • Tell patient that sustained-release tablet should not be crushed or chewed.
  • Instruct patient/family how to take pulse. Advise them to check pulse prior to each dose and to contact health care provider if rate or rhythm changes.
  • Advise patient to carry identification (eg, Medi-Alert) indicating disease and drug therapy at all times.
  • Advise patient to notify other health care providers/dentist prior to other therapy/surgery.
  • Emphasize importance of regular medical follow-up, even in absence of side effects or problems related to this drug therapy.
  • Caution patient to wear dark glasses as needed to decrease light sensitivity and inform patient that dark glasses may be needed both indoors and outside.
  • Instruct patient to report these symptoms to health care provider immediately: Visual disturbances (eg, blurring), tinnitus, bleeding, bruising, fever, headache, dizziness, severe diarrhea, or skin rash/eruption.
  • Advise patient that drug causes dizziness and blurred vision and to use caution while driving or performing other tasks requiring mental alertness.
  • Caution patient to avoid exposure to sunlight and to use sunscreen or wear protective clothing to avoid photosensitivity reaction.
  • Instruct patient not to take otc medications without consulting health care provider.

Popularity: 2% [?]


If you're still unable to find appropriate information in the article, please use search form below